Dubertret 1989.

Study characteristics
Methods	RCT, active‐controlled Date of study: July 1987 ‐ January 1988 Location: Paris, France
Participants	Randomised: 37 participants (mean age, sex ratio: not stated) Inclusion criteria Participants with moderate‐severe psoriasis: widespread psoriasis (PASI > 18) Exclusion criteria Not stated Dropouts and withdrawals Not stated
Interventions	Intervention A. Cyclosporin (n = 18), orally, 2.5 mg/kg/d Control intervention B. Cyclosporin (n = 19), orally, 5 mg/kg/d
Outcomes	Time to assessment for the primary outcome: not stated Primary outcomes of the trial PASI 75 Secondary outcomes of the trial Not stated
Notes	Funding: not stated, but 1 out of 4 authors was a staff member of Sandoz pharmaceutical company Declarations of interest: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote (p 136): "The patients were randomised..." Comment: no description of the method used to guarantee random sequence generation
Allocation concealment (selection bias)	Unclear risk	Quote (p 136): "The patients were randomised..." Comment: no description of the method used to guarantee allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	High risk	Comment: not specified as blinded
Blinding of outcome assessment (detection bias) All outcomes	High risk	Comment: not specified as blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Randomly assigned 37, analysed 37 Dropouts and withdrawals Not stated Management of missing data: no description of the method used to guarantee management of missing data
Selective reporting (reporting bias)	Unclear risk	Comment: no protocol was available. The prespecified outcomes mentioned in the Methods section appeared to have been reported